Skip to main content

In-vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment

Thursday, November 07, 2013 — Poster Session II

12:00 p.m. – 2:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • Y. Ardeshirpour
  • V. Chernomordik
  • M. Hassan
  • R. Zielinski
  • J. Capala
  • A.H. Gandjbakhche


Recent advances in monoclonal antibodies (mAb) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and their binding process to the therapy would provide means for early evaluation the efficacy of therapeutic intervention. In this study, we used in-vivo fluorescence lifetime imaging, which is an imaging technique based on the exponential decay rate of fluorescent signal, to monitor the efficacy of treatment with 17-DMAG on Human Epidermal Growth Factor 2 (HER2) positive tumors. HER2 specific Affibody conjugated to NIR fluorescent dye was injected it to nude mice with HER2 positive tumors. The fluorescence lifetime was monitored after 12 hours and a week after the last treatment and the correlation between the fluorescence lifetime and the efficacy of the treatment was studied.

back to top